Analysts were impressed by Phase 1 study results for two “T-cell engagers” Janux is developing for prostate cancer and other solid tumors.Dive Brief:Shares in Janux Therapeutics tripled in value Tuesday on early clinical trial results that analysts viewed as a signal the biotechnology company’s technology may yield safer and more potent immunotherapies for solid tumors.The […]
